Zimmer Biomet Announces First Quarter 2025 Financial Results

Rhea-AI Summary

Zimmer Biomet (NYSE: ZBH) reported its Q1 2025 financial results with net sales of $1.909 billion, showing a 1.1% increase year-over-year and 2.3% growth on a constant currency basis. The company posted net earnings of $182.0 million, with diluted EPS of $0.91 and adjusted EPS of $1.81.

The company updated its full-year 2025 guidance following the Paragon 28 acquisition, projecting reported revenue growth of 5.7% - 8.2% and adjusted EPS of $7.90 - $8.10. Notable highlights include strong performance in U.S. Hips driven by the Z1™ Triple-Taper Femoral Hip System and HAMMR® System, FDA clearance for Persona® Revision SoluTion™ Femur, and the completion of the Paragon 28 acquisition to strengthen their foot and ankle segment.

Geographic performance showed U.S. sales of $1.11 billion (+1.3%) and International sales of $795.5 million (+3.7% constant currency).

Positive

• Successful completion of Paragon 28 acquisition, expanding presence in high-growth foot and ankle segment
• FDA clearance for Persona® Revision SoluTion™ Femur, expanding product portfolio
• Strong performance in U.S. Hips segment with 3.7% growth
• S.E.T. category showed robust growth of 4.9% on constant currency basis
• Projected full-year revenue growth of 5.7% - 8.2%, including acquisitions

Negative

• Technology & Data, Bone Cement and Surgical segment declined 4.7%
• Reduced full-year 2025 adjusted EPS guidance to $7.90-$8.10 from previous $8.15-$8.35
• International Hips segment showed negative growth of -2.0% on reported basis
• Modest overall revenue growth of just 1.1% year-over-year

Insights

Financial Analyst

Zimmer Biomet delivered modest 1.1% growth but lowered EPS guidance despite revenue outlook increase, reflecting acquisition and tariff pressures.

Zimmer Biomet's Q1 2025 presents a mixed financial picture. The company posted $1.909 billion in sales, representing modest growth of 1.1% year-over-year (2.3% constant currency). Adjusted EPS reached $1.81, while GAAP EPS was $0.91.

The most significant development is the company's updated guidance following its Paragon 28 acquisition. While projected revenue growth increased substantially from 1.0-3.5% to 5.7-8.2%, adjusted EPS guidance was reduced from $8.15-$8.35 to $7.90-$8.10. This divergence suggests the acquisition will be revenue-accretive but earnings-dilutive in the near term, with additional pressure from proposed tariffs.

Looking at segment performance, U.S. Hip sales showed strength at 3.7% growth, while the Technology segment declined 4.7%. The S.E.T. category (Sports Medicine, Extremities, Trauma, etc.) performed well with 3.9% growth.

Notably, the company's organic constant currency revenue growth guidance remains unchanged at 3.0-5.0%, indicating management expects acceleration in coming quarters to meet full-year targets, particularly from new product introductions like the Oxford Cementless Partial Knee. This quarter appears to represent strategic positioning for future growth at the expense of near-term profitability.

Medical Device Industry Expert

Strategic expansion into high-growth foot and ankle segment through Paragon 28 acquisition bolsters portfolio despite short-term financial impact.

Zimmer Biomet's Q1 results showcase a company actively reshaping its portfolio for future growth. The completed acquisition of Paragon 28 represents a strategic expansion into the high-growth foot and ankle segment, providing dedicated commercial channels in a specialized orthopedic niche.

The company's innovation pipeline shows meaningful progression, particularly in hip reconstruction. The new Z1™ Triple-Taper Femoral Hip System and HAMMR® Automated Hip Surgical Impactor System are driving the 3.7% growth in U.S. hip sales. These innovations align with industry trends toward procedure-specific instrumentation and navigation capabilities.

FDA clearance for the Persona® Revision SoluTion™ Femur implant addresses the growing demand for metal-sensitive options, though its Q3 commercial availability means revenue impact won't materialize until later this year. The company's focus on ASCs with the ZBX™ offering demonstrates awareness of the ongoing site-of-care shift in orthopedics.

Knees, traditionally Zimmer's stronghold, showed modest 0.6% growth, suggesting market share challenges. However, management's optimism about the Oxford® Cementless Partial Knee indicates potential acceleration in the partial knee segment, which has been gaining popularity for its less invasive approach and faster recovery times.

The leadership changes, including CEO Ivan Tornos taking on the Chairman role, suggest continued commitment to the current strategic direction focused on innovation and portfolio diversification.

• First quarter net sales of $1.909 billion increased 1.1% and 2.3% on a constant currency¹ basis
• First quarter diluted earnings per share were $0.91; adjusted¹ diluted earnings per share were $1.81
• Company updates full-year 2025 reported revenue guidance to include the Paragon 28 acquisition and currency expectations, and full-year 2025 adjusted¹ earnings per share guidance to include Paragon 28, currency and the impact from current tariff proposals

WARSAW, Ind., May 5, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter ended March 31, 2025.  The Company reported first quarter net sales of $1.909 billion, an increase of 1.1% over the prior year period, and an increase of 2.3% on a constant currency¹ basis.  Net earnings for the first quarter were $182.0 million, or $361.1 million on an adjusted¹ basis.

Diluted earnings per share were $0.91 for the first quarter, and adjusted¹ diluted earnings per share were $1.81. 

1 Reconciliations of these measures to the corresponding U.S. generally accepted accounting principles measures are included in this press release.

"We are proud of our team's continued execution and performance to start the year, as we delivered solid first quarter results and advanced our bold innovation agenda," said Ivan Tornos, Zimmer Biomet's President and Chief Executive Officer.  "We're excited about the momentum in U.S. Hips, fueled by our revamped portfolio inclusive of the Z1™ Triple-Taper Femoral Hip System, HAMMR^® Automated Hip Surgical Impactor System, as well as navigation capabilities, and believe the early enthusiasm from surgeons for our new Oxford^® Cementless Partial Knee positions us well to accelerate growth in the second half of the year.  The recently completed acquisition of Paragon 28 is another bold step toward our innovation and diversification ambitions, expanding our S.E.T. business with leading technologies and a dedicated commercial channel in the high-growth foot and ankle segment."

Recent Highlights

• Completed the acquisition of Paragon 28, Inc., a leading medical device company focused exclusively on the foot and ankle orthopedic segment, further strengthening Zimmer Biomet's position in this high-growth space.
• Showcased a broad portfolio of innovations at the 2025 American Academy of Orthopaedic Surgeons (AAOS) annual meeting, including a comprehensive hip portfolio anchored by the new Z1™ Triple-Taper Femoral Hip System, along with the latest technologies for knee and upper extremity reconstruction and key robotic solutions. In addition, Zimmer Biomet debuted ZBX™, its new Ambulatory Surgery Center (ASC) offering to surgeons and institutions looking to expand their orthopedic footprint.
• Received U.S. Food and Drug Administration (FDA) 510(k) clearance of Persona^® Revision SoluTion™ Femur, a revision knee implant component offering an alternative for patients with sensitivities to certain metals. The product will be commercially available in the U.S. in Q3 2025.
• Launched the You'll Be Back Campaign with Chief Movement Officer Arnold Schwarzenegger, providing millions of people living with joint pain with an online community that empowers them with resources to make informed choices about their mobility.
• Announced upcoming changes to Zimmer Biomet's Board of Directors, effective at the Company's annual meeting of stockholders on May 29, 2025, including the retirement of Non-Executive Chairman Christopher Begley; the appointment of President and CEO Ivan Tornos as Chairman of the Board upon Mr. Begley's retirement; and the naming of Michael Farrell as Lead Independent Director upon Mr. Begley's retirement.
• Appointed Jehanzeb Noor as Senior Vice President, Chief Strategy, Innovation and Business Development Officer, and Kristen Cardillo as Senior Vice President, Chief Communications Officer, to the Zimmer Biomet Executive Leadership Team.
• Named one of the 2025 World's Most Ethical Companies^® by Ethisphere.

Geographic and Product Category Sales

The following sales table provides results by geography and product category for the three-month period ended March 31, 2025, as well as the percentage change compared to the applicable prior year period, on both a reported basis and a constant currency basis.

NET SALES - THREE MONTHS ENDED MARCH 31, 2025
(in millions, unaudited)
										Constant
	Net									Currency
	Sales				% Change					% Change
Geographic Results
United States	$	1,113.6				1.3		%			1.3		%
International		795.5				0.7					3.7
Total	$	1,909.1				1.1		%			2.3		%
Product Categories
Knees
United States	$	459.0				0.2		%			0.2		%
International		333.9				1.2					4.2
Total		792.9				0.6					1.9
Hips
United States		264.3				3.7					3.7
International		231.5				(2.0)					1.0
Total		495.8				0.9					2.4
S.E.T. *		470.5				3.9					4.9
Technology & Data, Bone Cement and Surgical **		149.9				(4.7)					(3.5)
Total	$	1,909.1				1.1		%			2.3		%

* Sports Medicine, Extremities, Trauma, Craniomaxillofacial and Thoracic

** Historically referred to as "Other"

Amounts reported in millions are computed based on the actual amounts.  As a result, the sum of the components reported in millions may not equal the total amount reported in millions due to rounding.  Percentages presented are calculated from the underlying unrounded amounts.

Financial Guidance

The Company is updating its full-year 2025 reported revenue guidance to include the Paragon 28, Inc. ("Paragon 28") acquisition and currency expectations, and full-year 2025 adjusted earnings per share guidance to include Paragon 28, currency and the impact from current tariff proposals:

Projected Year Ending December 31, 2025
	Previous Guidance	Updated Guidance
2025 Reported Revenue Change	1.0% - 3.5%	5.7% - 8.2%
Foreign Currency Exchange Impact	(2.0)% - (1.5)%	0.0% - 0.5%
2025 Constant Currency Revenue Change	N/A	5.7% - 7.7%
2025 Organic Constant Currency Revenue Change(1)	3.0% - 5.0%	3.0% - 5.0%
Adjusted Diluted EPS(2)	$8.15 - $8.35	$7.90 - $8.10

(1)	Excludes the projected impact of the Paragon 28 acquisition.  Reconciliation of this measure to the most directly comparable GAAP financial measure is included in this press release.
(2)	These measures are non-GAAP financial measures for which a reconciliation to the most directly comparable GAAP financial measure is not available without unreasonable efforts.  See "Forward-Looking Non-GAAP Financial Measures" below, which identifies the information that is unavailable without unreasonable efforts and provides additional information.  It is probable that these forward-looking non-GAAP financial measures may be materially different from the corresponding GAAP financial measures.

Conference Call

The Company will conduct its first quarter investor conference call today, May 5, 2025, at 8:30 a.m. ET.  The audio webcast can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com.  It will be archived for replay following the conference call. 

About the Company

Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health.  We seamlessly transform the patient experience through our innovative products and suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. 

With 90+ years of trusted leadership and proven expertise, Zimmer Biomet is positioned to deliver the highest quality solutions to patients and providers.  Our legacy continues to come to life today through our progressive culture of evolution and innovation.

For more information about our product portfolio, our operations in 25+ countries and sales in 100+ countries or about joining our team, visit www.zimmerbiomet.com or follow on LinkedIn at www.linkedin.com/company/zimmerbiomet or X / Twitter at www.x.com/zimmerbiomet.  

Website Information

We routinely post important information for investors on our website, www.zimmerbiomet.com, in the "Investor Relations" section.  We use this website as a means of disclosing material, non-public information and for complying with our disclosure obligations under Regulation FD.  Accordingly, investors should monitor the Investor Relations section of our website, in addition to following our press releases, SEC filings, public conference calls, presentations and webcasts. 

The information contained on, or that may be accessed through, our website or any other website referenced herein is not incorporated by reference into, and is not a part of, this document.

Note on Non-GAAP Financial Measures

This press release and our commentary in our investor conference call today include non-GAAP financial measures that differ from financial measures calculated in accordance with U.S. generally accepted accounting principles ("GAAP").  These non-GAAP financial measures may not be comparable to similar measures reported by other companies and should be considered in addition to, and not as a substitute for, or superior to, other measures prepared in accordance with GAAP.

Net sales change information for the three-month period ended March 31, 2025 is presented on a GAAP (reported) basis and on a constant currency basis.  Projected net sales change information for the year ended December 31, 2025, is also presented on an organic constant currency basis.  Constant currency percentage changes exclude the effects of foreign currency exchange rates.  They are calculated by translating current and prior-period sales at the same predetermined exchange rate.  The translated results are then used to determine year-over-year percentage increases or decreases.  In addition to excluding the projected effects of foreign currency exchange rates, projected 2025 organic constant currency revenue change also excludes the projected impact on net sales from the April 2025 acquisition of Paragon 28.

Net earnings and diluted earnings per share for the three-month periods ended March 31, 2025 and 2024 are presented on a GAAP (reported) basis and on an adjusted basis.  These adjusted financial measures exclude the effects of certain items, which are detailed in the reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures presented later in the press release. 

Free cash flow is an additional non-GAAP measure that is presented in this press release.  Free cash flow is computed by deducting additions to instruments and other property, plant and equipment from net cash provided by operating activities.

Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures are included in this press release.  This press release also contains supplemental reconciliations of additional non-GAAP financial measures that the Company presents in other contexts.  These additional non-GAAP financial measures are computed from the most directly comparable GAAP financial measure as indicated in the applicable reconciliation.

Management uses non-GAAP financial measures internally to evaluate the performance of the business.  Additionally, management believes these non-GAAP measures provide meaningful incremental information to investors to consider when evaluating the performance of the Company.  Management believes these measures offer the ability to make period-to-period comparisons that are not impacted by certain items that can cause dramatic changes in reported income but that do not impact the fundamentals of our operations.  The non-GAAP measures enable the evaluation of operating results and trend analysis by allowing a reader to better identify operating trends that may otherwise be masked or distorted by these types of items that are excluded from the non-GAAP measures.  In addition, constant currency revenue, adjusted operating profit, adjusted diluted earnings per share and free cash flow are used as performance metrics in our incentive compensation programs.

Forward-Looking Non-GAAP Financial Measures

This press release and our commentary in our investor conference call today also include certain forward-looking non-GAAP financial measures for the year ending December 31, 2025.  We calculate forward-looking non-GAAP financial measures based on internal forecasts that omit certain amounts that would be included in GAAP financial measures.  For instance, we exclude the impact of certain charges related to initial compliance with the European Union Medical Device Regulation; restructuring and other cost reduction initiatives; acquisition, integration, divestiture and related; and certain legal and tax matters.  We have not provided quantitative reconciliations of these forward-looking non-GAAP financial measures to the most directly comparable forward-looking GAAP financial measures because the excluded items are not available on a prospective basis without unreasonable efforts.  For example, the timing of certain transactions is difficult to predict because management's plans may change.  In addition, the Company believes such reconciliations would imply a degree of precision and certainty that could be confusing to investors.  It is probable that these forward-looking non-GAAP financial measures may be materially different from the corresponding GAAP financial measures.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding financial guidance, statements regarding macro pressures, including the impact of such pressures on our business, and any statements about our forecasts, expectations, plans, intentions, strategies or prospects.  All statements other than statements of historical or current fact are, or may be deemed to be, forward-looking statements.  Such statements are based upon the current beliefs, expectations and assumptions of management and are subject to significant risks, uncertainties and changes in circumstances that could cause actual outcomes and results to differ materially from the forward-looking statements.  These risks, uncertainties and changes in circumstances include, but are not limited to: competition; pricing pressures; dependence on new product development, technological advances and innovation; changes in customer demand for our products and services caused by demographic changes, obsolescence, development of different therapies or other factors; our ability to attract, retain, develop and maintain adequate succession plans for the highly skilled employees, senior management, independent agents and distributors we need to support our business; shifts in the product category or regional sales mix of our products and services; the risks and uncertainties related to our ability to successfully execute our restructuring plans; control of costs and expenses; risks related to the ability to realize the anticipated benefits of the acquisition of Paragon 28, including the possibility that the expected benefits from the transaction will not be realized or will not be realized within the expected time period; the risk that the businesses of Paragon 28 will not be integrated successfully; disruption from the proposed transaction making it more difficult to maintain business and operational relationships, including with customers, vendors, service providers, independent sales representatives, agents or agencies; the effects of business disruptions affecting us, our suppliers, customers or payors, either alone or in combination with other risks on our business and operations; the risks and uncertainties related to our ability to successfully integrate the operations, products, employees and distributors of acquired companies; the effect of the potential disruption of management's attention from ongoing business operations due to integration matters related to mergers and acquisitions; the effect of mergers and acquisitions on our relationships with customers, suppliers and lenders and on our operating results and businesses generally; unplanned delays, disruptions and expenses attributable to our enterprise resource planning and other system updates; the ability to form and implement alliances; dependence on a limited number of suppliers for key raw materials and other inputs and for outsourced activities; the risk of disruptions in the supply of materials and components used in manufacturing or sterilizing our products; breaches or failures of our (or of our business partners' or other third parties') information technology systems or products, including by cyberattack, unauthorized access or theft; the outcome of government investigations; the impact of healthcare reform and cost containment measures, including efforts sponsored by government agencies, legislative bodies, the private sector and healthcare purchasing organizations, through reductions in reimbursement levels, repayment demands and otherwise; the impact of substantial indebtedness on our ability to service our debt obligations and/or refinance amounts outstanding under our debt obligations at maturity on terms favorable to us, or at all; changes in tax obligations arising from examinations by tax authorities and from changes in tax laws in jurisdictions where we do business, including as a result of the "base erosion and profit shifting" project undertaken by the Organisation for Economic Co-operation and Development and otherwise; challenges to the tax-free nature of the ZimVie Inc. spinoff transaction and the subsequent liquidation of our retained interest in ZimVie Inc.; the risk of additional tax liability due to the recategorization of our independent agents and distributors to employees; changes in tariffs relating to imports to the U.S. and other countries; the risk that material impairment of the carrying value of our intangible assets, including goodwill, could negatively affect our operating results; changes in general domestic and international economic conditions, including interest rate and currency exchange rate fluctuations; changes in general industry and market conditions, including domestic and international growth, inflation and currency exchange rates; the domestic and international business impact of political, social and economic instability, tariffs, trade restrictions and embargoes, sanctions, wars, disputes and other conflicts, including on our ability to operate in, export from or collect accounts receivable in affected countries; challenges relating to changes in and compliance with governmental laws and regulations affecting our U.S. and international businesses, including regulations of the U.S. Food and Drug Administration ("FDA") and other government regulators relating to medical products, healthcare fraud and abuse laws and data privacy and cybersecurity laws; the success of our quality and operational excellence initiatives; the ability to remediate matters identified in inspectional observations issued by the FDA and other regulators, while continuing to satisfy the demand for our products; product liability, intellectual property and commercial litigation losses; and the ability to obtain and maintain adequate intellectual property protection.  A further list and description of these risks and uncertainties and other factors can be found in our Annual Report on Form 10-K for the year ended December 31, 2024, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and our subsequent filings with the Securities and Exchange Commission (SEC).  Copies of these filings are available online at www.sec.gov, www.zimmerbiomet.com or on request from us. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in our filings with the SEC.  Forward-looking statements speak only as of the date they are made, and we expressly disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Readers of this press release are cautioned not to rely on these forward-looking statements since there can be no assurance that these forward-looking statements will prove to be accurate.  This cautionary note is applicable to all forward-looking statements contained in this press release.

Note: Amounts reported in millions within this press release are computed based on the actual amounts.  As a result, the sum of the components reported in millions may not equal the total amount reported in millions due to rounding.  Certain columns and rows within tables may not add due to the use of rounded numbers.  Percentages presented are calculated from the underlying unrounded amounts.

ZIMMER BIOMET HOLDINGS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS
FOR THE THREE MONTHS ENDED MARCH 31, 2025 and 2024
(in millions, except per share amounts, unaudited)
	2025				2024
Net Sales	$	1,909.1			$	1,889.2
Cost of products sold, excluding intangible asset amortization		549.8				512.3
Intangible asset amortization		151.0				142.1
Research and development		110.6				107.9
Selling, general and administrative		758.8				736.2
Restructuring and other cost reduction initiatives		36.0				124.4
Acquisition, integration, divestiture and related		10.6				0.4
Operating expenses		1,616.8				1,623.3
Operating Profit		292.3				265.9
Other income (expense), net		2.9				(0.1)
Interest expense, net		(66.2)				(50.7)
Earnings before income taxes		229.0				215.1
Provision for income taxes		46.5				42.3
Net Earnings		182.6				172.8
Less: Net earnings attributable to noncontrolling interest		0.6				0.4
Net Earnings of Zimmer Biomet Holdings, Inc.	$	182.0			$	172.4
Earnings Per Common Share
Basic	$	0.92			$	0.84
Diluted	$	0.91			$	0.84
Weighted Average Common Shares Outstanding
Basic		198.9				205.2
Diluted		199.7				206.2

 

ZIMMER BIOMET HOLDINGS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in millions, unaudited)
		March 31,				December 31,
		2025				2024
Assets
Cash and cash equivalents		$	1,384.5			$	525.5
Receivables, net			1,533.4				1,480.7
Inventories			2,244.2				2,235.3
Other current assets			428.2				430.1
Total current assets			5,590.2				4,671.5
Property, plant and equipment, net			2,064.9				2,048.8
Goodwill			8,988.6				8,951.1
Intangible assets, net			4,468.0				4,598.4
Other assets			1,072.1				1,095.5
Total Assets		$	22,183.9			$	21,365.3
Liabilities and Stockholders' Equity
Current liabilities		$	1,695.0			$	1,587.9
Current portion of long-term debt			600.0				863.0
Other long-term liabilities			908.9				1,096.6
Long-term debt			6,576.3				5,341.6
Stockholders' equity			12,403.8				12,476.2
Total Liabilities and Stockholders' Equity		$	22,183.9			$	21,365.3

 

ZIMMER BIOMET HOLDINGS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE THREE MONTHS ENDED MARCH 31, 2025 and 2024
(in millions, unaudited)
		2025				2024
Cash flows provided by (used in) operating activities
Net earnings		$	182.6			$	172.8
Depreciation and amortization			254.4				238.6
Share-based compensation			19.6				29.0
Changes in operating assets and liabilities, net of acquired assets and liabilities
Income taxes			(15.6)				(8.6)
Receivables			(18.8)				(22.7)
Inventories			(3.0)				(55.3)
Accounts payable and accrued liabilities			(36.4)				(119.4)
Other assets and liabilities			(0.1)				(6.4)
Net cash provided by operating activities			382.8				228.0
Cash flows provided by (used in) investing activities
Additions to instruments			(59.7)				(82.0)
Additions to other property, plant and equipment			(44.6)				(55.1)
Net investment hedge settlements			1.0				10.2
Acquisition of intangible assets			(2.4)				(43.3)
Other investing activities			(0.3)				(24.8)
Net cash used in investing activities			(106.0)				(195.0)
Cash flows provided by (used in) financing activities
Net payments on revolving facilities			-				70.0
Proceeds from senior notes			1,748.1				-
Redemption of senior notes			(863.0)				-
Dividends paid to stockholders			(47.8)				(49.4)
Proceeds from employee stock compensation plans			16.7				56.4
Business combination contingent consideration payments			(17.4)				(1.5)
Debt issuance costs			(16.1)				-
Deferred business combination payments			-				(1.5)
Repurchase of common stock			(229.8)				(113.6)
Other financing activities			(15.2)				(10.5)
Net cash provided by (used in) financing activities			575.4				(50.1)
Effect of exchange rates on cash and cash equivalents			7.0				(5.7)
Change in cash and cash equivalents			859.1				(22.7)
Cash and cash equivalents, beginning of year			525.5				415.8
Cash and cash equivalents, end of period		$	1,384.5			$	393.0

 

ZIMMER BIOMET HOLDINGS, INC.
RECONCILIATION OF REPORTED NET SALES % CHANGE TO
CONSTANT CURRENCY % CHANGE
(unaudited)
	For the Three Months Ended
	March 31, 2025 vs. 2024
						Foreign					Constant
						Exchange					Currency
	% Change					Impact					% Change
Geographic Results
United States		1.3		%			-		%			1.3		%
International		0.7					(3.0)					3.7
Total		1.1		%			(1.2)		%			2.3		%
Product Categories
Knees
United States		0.2		%			-		%			0.2		%
International		1.2					(3.0)					4.2
Total		0.6					(1.3)					1.9
Hips
United States		3.7					-					3.7
International		(2.0)					(3.0)					1.0
Total		0.9					(1.5)					2.4
S.E.T.		3.9					(1.0)					4.9
Technology & Data, Bone Cement and Surgical		(4.7)					(1.2)					(3.5)
Total		1.1		%			(1.2)		%			2.3		%

 

ZIMMER BIOMET HOLDINGS, INC.
RECONCILIATION OF PROJECTED FULL-YEAR 2025 REPORTED REVENUE CHANGE TO
ORGANIC CONSTANT CURRENCY REVENUE CHANGE
(unaudited)
	Projected
	Full-year 2025
Reported revenue change	5.7 - 8.2	%
Less: Foreign currency exchange impact	0.0 - 0.5
Less: Paragon 28	2.7
Organic constant currency revenue change	3.0 - 5.0	%

 

ZIMMER BIOMET HOLDINGS, INC.
RECONCILIATION OF REPORTED TO ADJUSTED RESULTS
FOR THE THREE MONTHS ENDED MARCH 31, 2025 and 2024
(in millions, except per share amounts, unaudited)
FOR THE THREE MONTHS ENDED MARCH 31, 2025
		Cost of products sold, excluding intangible asset amortization				Intangible asset amortization				Research and development				Restructuring and other cost reduction initiatives				Acquisition, integration, divestiture and related				Interest expense, net				Provision for income taxes				Net Earnings of Zimmer Biomet Holdings, Inc.				Diluted earnings per common share
As Reported		$	549.8			$	151.0			$	110.6			$	36.0			$	10.6			$	(66.2)			$	46.5			$	182.0			$	0.91
Inventory and manufacturing- related charges(1)			(6.2)				-				-				-				-				-				2.1				4.1				0.02
Intangible asset amortization(2)			-				(151.0)				-				-				-				-				28.2				122.8				0.61
Restructuring and other cost reduction initiatives(3)			-				-				-				(36.0)				-				-				7.2				28.8				0.14
Acquisition, integration, divestiture and related(4)			-				-				-				-				(10.6)				-				1.9				8.7				0.04
European Union Medical Device Regulation(5)			-				-				(4.4)				-				-				-				0.9				3.5				0.02
Other charges(6)			-				-				-				-				-				4.8				2.7				2.1				0.01
Other certain tax adjustments(7)			-				-				-				-				-				-				(9.2)				9.2				0.05
As Adjusted		$	543.6			$	-			$	106.2			$	-			$	-			$	(61.4)			$	80.3			$	361.2			$	1.81

 

FOR THE THREE MONTHS ENDED MARCH 31, 2024
		Cost of products sold, excluding intangible asset amortization				Intangible asset amortization				Research and development				Selling, general and administrative				Restructuring and other cost reduction initiatives				Acquisition, integration, divestiture and related				Other income (expense), net				Provision for income taxes				Net Earnings of Zimmer Biomet Holdings, Inc.				Diluted earnings per common share
As Reported		$	512.3			$	142.1			$	107.9			$	736.2			$	124.4			$	0.4			$	(0.1)			$	42.3			$	172.4			$	0.84
Inventory and manufacturing- related charges(1)			(1.1)				-				-				-				-				-				-				0.8				0.3				-
Intangible asset amortization(2)			-				(142.1)				-				-				-				-				-				27.8				114.3				0.55
Restructuring and other cost reduction initiatives(3)			-				-				-				-				(124.4)				-				-				27.8				96.6				0.47
Acquisition, integration, divestiture and related(4)			-				-				-				-				-				(0.4)				-				0.4				-				-
European Union Medical Device Regulation(5)			-				-				(5.7)				-				-				-				-				1.3				4.4				0.02
Other charges(6)			-				-				-				0.2				-				-				2.3				0.5				1.6				0.01
Other certain tax adjustments(7)			-				-				-				-				-				-				-				(10.0)				10.0				0.05
As Adjusted		$	511.2			$	-			$	102.2			$	736.4			$	-			$	-			$	2.1			$	90.9			$	399.7			$	1.94

(1)	Inventory and manufacturing-related charges include excess and obsolete inventory charges on certain product lines we intend to discontinue, the acceleration of depreciation and fixed overhead costs expensed immediately related to a manufacturing plant shutdown, and other inventory and manufacturing-related charges or gains.
(2)	We exclude intangible asset amortization as well as deferred tax rate changes on our intangible assets from our non-GAAP financial measures because we internally assess our performance against our peers without this amortization.  Due to various levels of acquisitions among our peers, intangible asset amortization can vary significantly from company to company.
(3)	In December 2019, 2021 and 2023, and in February 2025, we initiated global restructuring programs that included a reorganization of key businesses and an overall effort to reduce costs in order to accelerate decision-making, focus the organization on priorities to drive growth and, in the case of the December 2021 program, to prepare for the spinoff of ZimVie, Inc. ("ZimVie").  Restructuring and other cost reduction initiatives also include other cost reduction and optimization initiatives that have the goal of reducing costs across the organization.  The costs include employee termination benefits; contract terminations for facilities and sales agents; and other charges, such as consulting fees, project management expenses, retention period salaries and benefits and relocation costs.
(4)	The acquisition, integration, divestiture and related gains and expenses we have excluded from our non-GAAP financial measures resulted from various acquisitions, post-separation costs we have incurred related to ZimVie and gains related to a transition services agreement for services we provide to ZimVie and a transition manufacturing and supply agreement for products we supply to ZimVie for a limited period.
(5)	The European Union Medical Device Regulation imposes significant additional premarket and postmarket requirements.  The new regulations provided a transition period until May 2021 for previously-approved medical devices to meet the additional requirements.  For certain devices, this transition period was extended until May 2024.  A conditional extension of the transition period has been implemented until December 2027 and 2028 depending on the legacy medical device's risk class.  We are excluding from our non-GAAP financial measures the incremental costs incurred to establish initial compliance with the regulations related to our previously-approved medical devices.  The incremental costs primarily relate to temporary personnel and third-party professionals necessary to supplement our internal resources.
(6)	We have incurred other various expenses from specific events or projects that we consider highly variable or that have a significant impact to our operating results that we have excluded from our non-GAAP measures.  These include gains and losses from changes in fair value on our equity investments, among other various costs.  In addition, in February 2025 we issued senior notes in order to have the necessary cash-on-hand to acquire Paragon 28 once regulatory approval was received.  We have excluded from our non-GAAP financial measures the interest on this debt related to the principal amount of the estimated purchase price and acquisition-related costs.
(7)	Other certain tax adjustments are related to certain significant and discrete tax adjustments including intercompany transactions between jurisdictions, ongoing impacts of tax only amortization resulting from certain restructuring transactions and impacts of significant tax reform including Swiss reform.

 

ZIMMER BIOMET HOLDINGS, INC.
RECONCILIATION OF NET CASH PROVIDED BY OPERATING
ACTIVITIES TO FREE CASH FLOW
FOR THE THREE MONTHS ENDED MARCH 31, 2025 and 2024
(in millions, unaudited)
	Three Months Ended March 31,
	2025				2024
Net cash provided by operating activities	$	382.8			$	228.0
Additions to instruments		(59.7)				(82.0)
Additions to other property, plant and equipment		(44.6)				(55.1)
Free cash flow	$	278.5			$	90.9

 

ZIMMER BIOMET HOLDINGS, INC.
RECONCILIATION OF GROSS PROFIT & MARGIN
TO ADJUSTED GROSS PROFIT & MARGIN
FOR THE THREE MONTHS ENDED MARCH 31, 2025 and 2024
(in millions, unaudited)
	Three Months Ended March 31,
	2025				2024
Net Sales	$	1,909.1			$	1,889.2
Cost of products sold, excluding intangible asset amortization		549.8				512.3
Intangible asset amortization		151.0				142.1
Gross Profit	$	1,208.3			$	1,234.8
Inventory and manufacturing-related charges		6.2				1.1
Intangible asset amortization		151.0				142.1
Adjusted gross profit	$	1,365.5			$	1,378.0
Gross margin		63.3		%		65.4		%
Inventory and manufacturing-related charges		0.3				0.1
Intangible asset amortization		7.9				7.5
Adjusted gross margin		71.5		%		72.9		%

 

ZIMMER BIOMET HOLDINGS, INC.
RECONCILIATION OF OPERATING PROFIT & MARGIN TO ADJUSTED OPERATING PROFIT & MARGIN
FOR THE THREE MONTHS ENDED MARCH 31, 2025 and 2024
(in millions, unaudited)
	Three Months Ended March 31,
	2025				2024
Operating profit	$	292.3			$	265.9
Inventory and manufacturing-related charges		6.2				1.1
Intangible asset amortization		151.0				142.1
Restructuring and other cost reduction initiatives		36.0				124.4
Acquisition, integration, divestiture and related		10.6				0.4
European Union Medical Device Regulation		4.4				5.7
Other charges		-				(0.2)
Adjusted operating profit	$	500.5			$	539.4
Operating profit margin		15.3		%		14.1		%
Inventory and manufacturing-related charges		0.3				0.1
Intangible asset amortization		7.9				7.5
Restructuring and other cost reduction initiatives		1.9				6.6
Acquisition, integration, divestiture and related		0.6				-
European Union Medical Device Regulation		0.2				0.3
Adjusted operating profit margin		26.2		%		28.6		%

 

ZIMMER BIOMET HOLDINGS, INC.
RECONCILIATION OF EFFECTIVE TAX RATE TO ADJUSTED EFFECTIVE TAX RATE
FOR THE THREE MONTHS ENDED MARCH 31, 2025 and 2024
(unaudited)
	Three Months Ended March 31,
	2025				2024
Effective tax rate		20.3		%		19.7		%
Tax effect of adjustments made to earnings before taxes(1)		1.9				3.4
Other certain tax adjustments (2)		(4.0)				(4.6)
Adjusted effective tax rate		18.2		%		18.5		%

(1) Includes inventory and manufacturing-related charges; intangible asset amortization; restructuring and other cost reduction initiatives; acquisition, integration, divestiture and related; litigation; European Union Medical Device Regulation; and other charges
(2) Other certain tax adjustments are related to certain significant and discrete tax adjustments including intercompany transactions between jurisdictions, ongoing impacts of tax only amortization resulting from certain restructuring transactions, and impacts of significant tax reform including Swiss reform.

 

ZIMMER BIOMET HOLDINGS, INC.
RECONCILIATION OF DEBT TO NET DEBT
AS OF MARCH 31, 2025 and DECEMBER 31, 2024
(in millions, unaudited)
	March 31, 2025				December 31, 2024
Debt, both current and long-term	$	7,176.3			$	6,204.6
Cash and cash equivalents		(1,384.5)				(525.5)
Net debt	$	5,791.8			$	5,679.1

 

Media	Investors
Heather Zoumas-Lubeski	David DeMartino
(445) 248-0577	(646) 531-6115
heather.zoumaslubeski@zimmerbiomet.com	david.demartino@zimmerbiomet.com
	Zach Weiner
	(908) 591-6955
	zach.weiner@zimmerbiomet.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/zimmer-biomet-announces-first-quarter-2025-financial-results-302445629.html

SOURCE Zimmer Biomet Holdings, Inc.

FAQ

What were Zimmer Biomet's (ZBH) Q1 2025 earnings results?

Zimmer Biomet reported Q1 2025 net sales of $1.909 billion (+1.1% YoY), net earnings of $182.0 million, diluted EPS of $0.91, and adjusted EPS of $1.81.

How did the Paragon 28 acquisition impact ZBH's 2025 guidance?

Following the Paragon 28 acquisition, ZBH updated its 2025 guidance to 5.7-8.2% reported revenue growth, up from previous 1.0-3.5%, though adjusted EPS guidance was lowered to $7.90-$8.10.

Which segments performed best for Zimmer Biomet in Q1 2025?

The S.E.T. segment showed 4.9% growth on constant currency basis, while U.S. Hips performed well with 3.7% growth. The U.S. market overall grew 1.3%.

What new products did Zimmer Biomet receive FDA approval for in Q1 2025?

ZBH received FDA 510(k) clearance for Persona® Revision SoluTion™ Femur, a revision knee implant for patients with metal sensitivities, scheduled for U.S. launch in Q3 2025.

What are the key changes in Zimmer Biomet's leadership for 2025?

CEO Ivan Tornos will become Chairman of the Board, replacing retiring Christopher Begley, with Michael Farrell becoming Lead Independent Director, effective May 29, 2025.